Baird Downgrades BioMarin Pharmaceutical To Neutral

Baird downgraded

from Outperform to Neutral. BioMarin Pharmaceutical shares have gained 109.81 percent over the past 52 weeks, while the S&P 500 index has surged 8.07 percent in the same period. BioMarin Pharmaceutical shares declined 1.41 percent to $136.70 in pre-market trading.